U.S. stocks rose modestly on Wednesday, with the Dow average nearing the psychologically important 20,000 level ahead of meeting minutes from the Federal Reserve.
The Dow Jones Industrial Average DJIA, +0.09% rose 32 points, or 0.2%, to 19,916, putting its about 84 points from the 20,000 level. The S&P 500 index SPX, +0.34% added 7 points, or 0.3%, to 2,265, hovering a few points below its all-time high set last month. Gains were broad-based, with nine of the 11 main sectors trading in the green.
The Nasdaq Composite Index COMP, +0.46% gained 23 points, or 0.4%, to 5,452.
“The Dow continues to sit tantalizingly close to that psychological 20,000 level, but the appetite to push higher still seems lacking,” said Remo Fritschi, institutional sales manager at ADS Securities, in a note.
Following U.S. Biotech Stocks are among the “Most Active” Stocks in the course of recent trading session, Wednesday:
Affimed NV (NASDAQ:AFMD), with shares dropped -1.19% is now trading at $2.10. The Stock is active as 75,071.00 shares changed hands versus its average volume of 181,833.00 shares. For investors focus on the performance of the stocks so the AFMD showed weekly ahead performance of 13.51% which was maintained for the month at 7.69%. Correspondingly the negative performance for the quarter was remained - 20.15% and if took notice on yearly performance that was - 68.61% whereas the year to date performance halted at 16.67%.
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, and The University of Texas MD Anderson Cancer Center recently declared an exclusive planned clinical development and commercialization partnership to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product.
“In our effort to broaden the applications of our NK-cell engager products, we are anxious to partner with the world-leading NK-cell experts at MD Anderson to investigate their unique product together with our first-in-class NK-cell engager AFM13 in Hodgkin lymphoma,” said Adi Hoess, Ph.D., CEO of Affimed. “Harnessing the advantages of both antibody-based and cell therapy approaches has the potential to better exploit the therapeutic activity of NK-cells. We believe this partnership could benefit many hematological malignancies, counting in multiple myeloma, where Affimed is developing AFM26, a BCMA/CD16A bispecific antibody. For us, this partnership is an important step in executing our strategy to develop transformative cancer therapies.”
“We look forward to joining the cord blood-derived NK-cells developed at MD Anderson with our collaborator’s technology which we believe will benefit our patients,” said Katayoun Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson.
Intra-Cellular Therapies Inc (NASDAQ:ITCI), with shares surged 3.19% is now trading at $16.28. The Stock is active as 74,994.00 shares changed hands versus its average volume of 702,258.00 shares. The stock is going forward its 52 week low with 50.00% and lagging behind from its 52 week high price with -70.73%. ITCI last month stock price volatility remained 6.32%.
Intra-Cellular Therapies, Inc. (ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently declared that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is planned to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The presentation is planned for Thursday, January 12, 2017 at 11:00 am PST (2:00 pm EST).
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, counting Parkinson’s and Alzheimer’s disease.